Pieter Cullis
Cullis, Pieter
Cullis, P. R.
VIAF ID: 3644149108567668780006 (Personal)
Permalink: http://viaf.org/viaf/3644149108567668780006
Preferred Forms
-
100 1 _ ‡a Cullis, P. R.
-
100 1 _
‡a
Cullis, Pieter
-
100 0 _
‡a
Pieter Cullis
4xx's: Alternate Name Forms (6)
Works
| Title | Sources |
|---|---|
| Alkylated derivatives of poly(ethylacrylic acid) can be inserted into preformed liposomes and trigger pH-dependent intracellular delivery of liposomal contents |
|
| Biodegradable lipids enabling rapidly eliminated lipid nanoparticles for systemic delivery of RNAi therapeutics |
|
| The Biomolecular Corona of Lipid Nanoparticles for Gene Therapy |
|
| Capillary electrophoresis frontal analysis for characterization of alphavbeta3 integrin binding interactions. |
|
| CaV 3.2 drives sustained burst-firing, which is critical for absence seizure propagation in reticular thalamic neurons. |
|
| Cellular gene transfer mediated by influenza virosomes with encapsulated plasmid DNA. |
|
| The cellular mechanisms of neuronal swelling underlying cytotoxic edema |
|
| Characterization of a liposomal copper(II)-quercetin formulation suitable for parenteral use |
|
| Characterization of the drug retention and pharmacokinetic properties of liposomal nanoparticles containing dihydrosphingomyelin |
|
| Deep Phenotyping by Mass Cytometry and Single Cell RNA-Sequencing Reveals LYN Regulated Signaling Profiles Underlying Monocyte Subset Heterogeneity and Lifespan |
|
| Development of a weak-base docetaxel derivative that can be loaded into lipid nanoparticles |
|
| Development of high-concentration lipoplexes for in vivo gene function studies in vertebrate embryos. |
|
| Distal cationic poly(ethylene glycol) lipid conjugates in large unilamellar vesicles prepared by extrusion enhance liposomal cellular uptake. |
|
| The effect of circulation lifetime and drug-to-lipid ratio of intravenously administered lipid nanoparticles on the biodistribution and immunostimulatory activity of encapsulated CpG-ODN |
|
| Entrapment of small molecules and nucleic acid-based drugs in liposomes |
|
| Factors limiting autogene-based cytoplasmic expression systems. |
|
| Formation of drug-arylsulfonate complexes inside liposomes: a novel approach to improve drug retention |
|
| A Glu-urea-Lys Ligand-conjugated Lipid Nanoparticle/siRNA System Inhibits Androgen Receptor Expression In Vivo |
|
| IGFBP2 is neither sufficient nor necessary for the physiological actions of leptin on glucose homeostasis in male ob/ob mice |
|
| The immunostimulatory activity of unmethylated and methylated CpG oligodeoxynucleotide is dependent on their ability to colocalize with TLR9 in late endosomes |
|
| Influence of Drug-to-Lipid Ratio on Drug Release Properties and Liposome Integrity in Liposomal Doxorubicin Formulations |
|
| Influence of Polyethylene Glycol Lipid Desorption Rates on Pharmacokinetics and Pharmacodynamics of siRNA Lipid Nanoparticles |
|
| Introducing pharmacogenetic testing with clinical decision support into primary care: a feasibility study |
|
| Investigation of factors responsible for cell line cytoplasmic expression differences |
|
| Light-Activated siRNA Endosomal Release (LASER) by Porphyrin Lipid Nanoparticles |
|
| Lipid-Based DNA Therapeutics: Hallmarks of Non-Viral Gene Delivery |
|
| Lipid nanoparticle delivery of glucagon receptor siRNA improves glucose homeostasis in mouse models of diabetes |
|
| Lipid Nanoparticle Delivery of siRNA to Silence Neuronal Gene Expression in the Brain |
|
| Lipid Nanoparticles Containing siRNA Synthesized by Microfluidic Mixing Exhibit an Electron-Dense Nanostructured Core |
|
| Lipid Nanoparticles Enabling Gene Therapies: From Concepts to Clinical Utility |
|
| Liposomal drug delivery systems: from concept to clinical applications |
|
| Liposomal nanomedicines: an emerging field |
|
| Liposome-encapsulated vincristine, vinblastine and vinorelbine: a comparative study of drug loading and retention |
|
| Microfluidic Synthesis of Highly Potent Limit-size Lipid Nanoparticles for In Vivo Delivery of siRNA. |
|
| The Niemann-Pick C1 Inhibitor NP3.47 Enhances Gene Silencing Potency of Lipid Nanoparticles Containing siRNA. |
|
| On the role of helper lipids in lipid nanoparticle formulations of siRNA |
|
| The Onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs |
|
| Optimization and characterization of a sphingomyelin/cholesterol liposome formulation of vinorelbine with promising antitumor activity |
|
| Personalized medicine revolution : how diagnosing and treating disease are about to change forever |
|
| Phospholipid-Free Small Unilamellar Vesicles for Drug Targeting to Cells in the Liver |
|
| PIAS1 modulates striatal transcription, DNA damage repair, and SUMOylation with relevance to Huntington’s disease |
|
| Preparation, Characterization, and Biological Analysis of Liposomal Formulations of Vincristine |
|
| Production of limit size nanoliposomal systems with potential utility as ultra-small drug delivery agents |
|
| Protective Effect of Edaravone against Cationic Lipid-Mediated Oxidative Stress and Apoptosis |
|
| Rapid synthesis of lipid nanoparticles containing hydrophobic inorganic nanoparticles. |
|
| Rational design of cationic lipids for siRNA delivery |
|
| Robust Microfluidic Technology and New Lipid Composition for Fabrication of Curcumin-Loaded Liposomes: Effect on the Anticancer Activity and Safety of Cisplatin |
|
| siRNA Lipid Nanoparticle Potently Silences Clusterin and Delays Progression When Combined with Androgen Receptor Cotargeting in Enzalutamide-Resistant Prostate Cancer |
|
| Spontaneous, solvent-free entrapment of siRNA within lipid nanoparticles |
|
| Sustained Depletion of FXIII-A by Inducing Acquired FXIII-B Deficiency |
|
| Synthesis and properties of novel tetraalkyl cationic lipids |
|
| Synthesis of a labeled RGD-lipid, its incorporation into liposomal nanoparticles, and their trafficking in cultured endothelial cells. |
|
| Synthetic methylated CpG ODNs are potent in vivo adjuvants when delivered in liposomal nanoparticles |
|
| Systemic Gene Silencing in Primary T Lymphocytes Using Targeted Lipid Nanoparticles |
|
| Systemic RNAi-mediated Gene Silencing in Nonhuman Primate and Rodent Myeloid Cells. |
|
| Systemic study of solvent-assisted active loading of gambogic acid into liposomes and its formulation optimization for improved delivery. |
|
| Therapeutically optimized rates of drug release can be achieved by varying the drug-to-lipid ratio in liposomal vincristine formulations. |
|
| Transfection properties of stabilized plasmid-lipid particles containing cationic PEG lipids |
|
| Triggered release of doxorubicin following mixing of cationic and anionic liposomes |
|
| Tunable pH-sensitive liposomes |
|
| Value-based healthcare delivery through metabolomics-based personalized health platform |
|
